A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Inclusion Criteria:

- patients between 3 months and 16 years of age;

- first solid organ transplant (eg, kidney, liver, heart);

- able to tolerate oral medication;

- females of childbearing potential must agree to utilize an effective method of
contraception throughout the study and for 90 days following discontinuation of study
drug;

- patients at risk of developing CMV disease (all transplant recipients other than
those who are D-R- for CMV).

Exclusion Criteria:

- patients who have previously participated in this study;

- patients who are participating in another clinical trial (except with the approval of
the Sponsor);

- severe, uncontrolled diarrhea (more than 5 watery stools per day);

- pregnant or lactating females.